Akcea Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$13.1M
Doctors Paid
3,781
Transactions
11,121
2024 Total
$19,219
Payment Breakdown by Category
Research$10.8M (82.4%)
Consulting$378,575 (2.9%)
Food & Beverage$281,261 (2.1%)
Travel$281,196 (2.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10.8M | 1,876 | 82.4% |
| Honoraria | $882,420 | 455 | 6.7% |
| Consulting Fee | $378,575 | 142 | 2.9% |
| Food and Beverage | $281,261 | 7,454 | 2.1% |
| Travel and Lodging | $281,196 | 756 | 2.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $265,937 | 142 | 2.0% |
| Grant | $123,500 | 6 | 0.9% |
| Space rental or facility fees (teaching hospital only) | $83,795 | 41 | 0.6% |
| Education | $3,996 | 248 | 0.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $249.00 | 1 | 0.0% |
Payments by Type
Research
$10.8M
1,876 transactions
General
$2.3M
9,245 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| ISIS 703802-CS2 | $2.1M | 0 | 152 |
| ISIS 678354-CS2 | $2.0M | 0 | 183 |
| A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and Nonalcoholic Fatty Liver Disease (NAFLD) | $1.0M | 0 | 243 |
| A 24-MONTH OPEN LABEL STUDY OF THE TOLERABILITY AND EFFICACY OF AN ANTISENSENSE OLIGONUCLEOTIDE (INOTERSEN) IN PATIENTS WITH TRANSTHYRETIN (TTR) AMYLOID CARDIOMYOPATHY | $919,318 | 0 | 53 |
| A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients With Hypertriglyceridemia and Established Cardiovascular Disease (CVD) or at a High Risk for CVD | $626,823 | 0 | 76 |
| PREVALENCE OF TTR AMYLOIDOSIS IN AMBULATORY PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION | $525,000 | 0 | 3 |
| A Randomized, Double-Blind, Placebo-Controlled, With an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy | $463,762 | 0 | 14 |
| TTR DEPOSITION AND SMALL NERVE FIBER COUNTS IN SKIN BIOPSIES | $275,847 | 0 | 2 |
| ISIS 703802-C S2 | $266,809 | 0 | 975 |
| A PROSPECTIVE, NON-INTERVENTIONAL, LONG-TERM, MULTINATIONAL COHORT SAFETY STUDY OF PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPATHY (HATTR-PN). | $254,569 | 0 | 68 |
| ST-2019-0301: Dr. Gaggin - Prevalence of TTR Amyloidosis in Ambulatory Patients with Heart Failure with Preserved Ejection Fraction | $250,000 | 0 | 1 |
| Risk Factors for Positive Tenosynovial Biopsy for Amyloidosis at Carpal Tunnel Release | $201,324 | 0 | 2 |
| CARDIO TTRANSSFORM NUCLEAR IMAGING STUDY (DISSOLVE) | $199,962 | 0 | 1 |
| SIS 304801-CS7 The APPROACH Open Label Study Volanesorsen (ISIS 304801) An Open-Label Study of Volanesorsen Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS) | $159,432 | 0 | 10 |
| ISIS 703802-CS5 | $155,005 | 0 | 10 |
| Amyloidosis Prevalence and Phenotype (TTRAPP study) | $138,677 | 0 | 1 |
| A PHASE 4 SAFETY STUDY ASSESSING THE ADVERSE EVENTS OCCURRING WITHIN ONE DAY OF TEGSEDI ADMINISTRATION IN PATIENTS WITH POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS. | $136,499 | 0 | 18 |
| Machine Learning for identification of wild-type and hereditary ATTR Amyloidosis | $123,050 | 0 | 3 |
| DETECTION OF SUBCLINICAL CARDIAC AMYLOIDOSIS IN ASYMPTOMATIC CARRIERS OF PATHOGENIC TTR VARIANT | $122,834 | 0 | 6 |
| Risk Factors for Postive Tenosynovial Biopsy for Amyloidosis at Carpal Tunnel Resease | $100,662 | 0 | 1 |
| TRAPP: observational study of patients with red-flag symptoms | $92,452 | 0 | 1 |
| TRAPP - observational study of patients with red-flag symptoms | $92,452 | 0 | 1 |
| PREDICTION OF THROMBOEMBOLISM RISK IN ATTR CARDIAC AMYLOIDOSIS | $75,000 | 0 | 1 |
| IST-2019-1101 - Machine Learning for identification of wild-type and hereditary ATTR Amyloidosis | $62,735 | 0 | 1 |
| ISIS 681257-CS6 | $56,146 | 0 | 14 |
| IMPROVING THE TIMING OF AMYLOID DETECTION VIA A MULTIDISCIPLINARY, THOMAS JEFFERSON UNIVERSITY NETWORK APPROACH | $53,912 | 0 | 5 |
| Volanesorsen Expanded Access Program (EAP) for Patients with Familial Chylomicronemia Syndrome (FCS) | $45,445 | 0 | 6 |
| confocal microscopy of Meissner's corpuscles to detect early amyloid deposition. | $25,725 | 0 | 1 |
| A PILOT STUDY ASSESSING THE UTILITY OF ULTRAHIGH-FREQUENCY ULTRASOUND IN THE EVALUATION OF CARPAL TUNNEL SYNDROM IN PATIENTS WITH hATTR | $19,219 | 0 | 1 |
| A PILOT STUDY ASSESSING THE UTILITY OF ULTRAHIGH-FREQUENCY ULTRASOUND IN THE EVALUATION OF CARPAL TUNNEL SYNDROM IN PATIENTS WITH HATTR | $19,219 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Andrew Darlington, Do, DO | Cardiovascular Disease | Fayetteville, GA | $157,385 | $0 |
| Dr. Chafic Karam, M.d, M.D | Neurology | Portland, OR | $124,341 | $0 |
| Sami Khella, Md, MD | Neurology | Philadelphia, PA | $99,304 | $0 |
| Richard Wright, M.d, M.D | Cardiovascular Disease | Santa Monica, CA | $84,004 | $0 |
| Said Beydoun, M.d, M.D | Neurology | Los Angeles, CA | $79,539 | $0 |
| Reynolds Delgado, M.d, M.D | Cardiovascular Disease | Houston, TX | $70,335 | $0 |
| Dr. David Wolinsky, M.d, M.D | Cardiovascular Disease | Weston, FL | $68,958 | $0 |
| Amanda Peltier, Md, MD | Neurology | Nashville, TN | $55,952 | $0 |
| Mr. Amin Yehya, Md, MD | Advanced Heart Failure and Transplant Cardiology | Norfolk, VA | $51,977 | $0 |
| Morie Gertz, M.d, M.D | Hematology | Rochester, MN | $45,804 | $0 |
| Thomas Brannagan, Md, MD | Neurology | New York, NY | $40,908 | $0 |
| Olakunle Akinboboye, Md Mph, MD MPH | Internal Medicine | Laurelton, NY | $37,579 | $0 |
| Kourosh Rezania | Neurology | Chicago, IL | $34,710 | $0 |
| Clement Eiswirth, Md, MD | Cardiovascular Disease | New Orleans, LA | $34,695 | $0 |
| Francisco Jimenez Carcamo, Md, MD | Cardiovascular Disease | South Miami, FL | $25,485 | $0 |
| Dr. Ugochukwu Egolum, Md, MD | Advanced Heart Failure and Transplant Cardiology | Gainesville, GA | $25,271 | $0 |
| Dr. Richard Moscicki, Md, MD | Allergy & Immunology | Boston, MA | $24,156 | $0 |
| Evgenia Raichlin, Md, MD | Cardiovascular Disease | Milwaukee, WI | $23,351 | $0 |
| Jeffrey Allen, M.d, M.D | Neurology | Minneapolis, MN | $22,819 | $0 |
| Dr. Eric Huang, M.d, M.D | Pediatric Endocrinology | Basking Ridge, NJ | $22,750 | $0 |
| Dmitry Yaranov, Md, MD | Cardiovascular Disease | Memphis, TN | $22,115 | $0 |
| Vance Wilson, Md, MD | Cardiovascular Disease | Daytona Beach, FL | $20,600 | $0 |
| Dr. Marcus Urey, Md, MD | Advanced Heart Failure and Transplant Cardiology | San Diego, CA | $18,726 | $0 |
| Unknown Provider | — | — | $17,338 | $0 |
| Andrew Pogozelski, M.d, M.D | Cardiovascular Disease | Pittsburgh, PA | $16,759 | $0 |
About Akcea Therapeutics, Inc.
Akcea Therapeutics, Inc. has made $13.1M in payments to 3,781 healthcare providers, recorded across 11,121 transactions in the CMS Open Payments database. In 2024, the company paid $19,219. The top product by payment volume is TEGSEDI ($3.6M).
Payments were distributed across 129 medical specialties. The top specialty by payment amount is Cardiovascular Disease ($717,559 to 956 doctors).
Payment categories include: Food & Beverage ($281,261), Consulting ($378,575), Research ($10.8M), Travel & Lodging ($281,196).
Akcea Therapeutics, Inc. is associated with 1 products in the CMS Open Payments database.